GlassScriptPhysician profile
Amanda G Smallmon
NPI 1447481072
$1,771.59
in general payments reported to CMS, 2019-2025
10 companies · $408 in 2025
The $408 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $126 · 2022: $256 · 2023: $191 · 2024: $790 · 2025: $408.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,289 · Travel and Lodging: $99.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,289.13 |
| Travel and Lodging | $99.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $785.99 | 2023-2025 | Spravato |
| Abbvie INC. | $484.57 | 2021-2024 | |
| Supernus Pharmaceuticals, INC. | $219.80 | 2025 | Qelbree |
| Axsome Therapeutics, INC. | $98.08 | 2024-2025 | Auvelity |
| Otsuka America Pharmaceutical, INC. | $66.95 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $45.95 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $27.67 | 2021-2023 | Ingrezza |
| Biogen, INC. | $23.14 | 2025 | Zurzuvae |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $13.04 | 2023 | |
| Genentech USA, INC. | $6.40 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Smallmon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.